DFTX trial shows DT120 100 mcg efficacy and safety in GAD
A phase III study reported that a single 100 microgram dose of DT120 produced rapid, robust, and durable efficacy with a favorable safety profile in GAD, outperforming placebo and the 50 microgram dose.